Показано 0 из 0
Дата |
---|
09.05.2024 |
08.05.2024 |
07.05.2024 |
06.05.2024 |
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.00
|
1.08
|
1.07
|
1.07
|
1.07
|
1.07
|
|
|
561.34
|
22.00
|
1.01
|
1.10
|
1.05
|
1.05
|
1.08
|
1.08
|
|
|
1 217.08
|
40.00
|
1.00
|
1.10
|
1.035
|
1.00
|
1.08
|
1.03
|
|
|
15 558.31
|
120.00
|
1.00
|
1.07
|
1.005
|
1.00
|
1.07
|
1.00
|
|
|
11 791.08
|
76.00
|
1.00
|
1.08
|
1.07
|
1.00
|
1.075
|
1.00
|
|
|
11 875.54
|
81.00
|
1.01
|
1.06
|
1.0599
|
1.01
|
1.0599
|
1.052
|
|
|
9 091.81
|
180.00
|
1.01
|
1.06
|
1.085
|
1.01
|
1.09
|
1.05
|
|
|
11 769.82
|
75.00
|
1.00
|
1.05
|
1.08
|
1.01
|
1.08
|
1.0499
|
|
|
20 140.84
|
111.00
|
1.00
|
1.08
|
1.02
|
1.02
|
1.08
|
1.069
|
|
|
13 470.94
|
59.00
|
1.00
|
1.13
|
1.07
|
1.02
|
1.07
|
1.02
|
|
|
14 726.60
|
106.00
|
Estrella Immunopharma, Inc. operates as a preclinical-stage biopharmaceutical company. The Company focuses on developing CD19 and CD22-targeted T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella Immunopharma serves customers worldwide.